Eddy Edson
Well-Known Member
- Relationship to Diabetes
- Type 2
Presentations start today.
Abstracts for all presentations: https://link.springer.com/article/10.1007/s00125-023-05969-6
Beyond CT-388, today’s session will offer data on retatrutide, cotadutide, survodutide, and pemvidutide. Then later we get data on tirzepatide – which is in line for FDA approval to treat obesity – from the SURMOUNT-4 study of weight maintenance out to 88 weeks of therapy. Yet another EASD session explores the mechanisms by which these multi-agonists may be acting in obesity and diabetes. In this session, we will get a glimpse of yet another GLP-1/GIP drug – CT-868.
.
.
.
This is a lot for all of us. Lifestyle medicine evangelists look at the world changing around them and they hardly know what to think. Some of them know that they hate it. They have a lifestyle program to sell and they seem to think that treating the physiologic problem of obesity is a threat to their business model. “Don’t make it complex when the metabolic impacts are obvious,” says one. “Ultraprocessed food consumption is designed to addict and adverse metabolic effects are imposed.”
We get it. If your whole world is built around coaching people with a minimal disease burden to prevent diabetes and obesity, then therapy for people with a bigger burden of disease is hard to comprehend.
But the fact is that many people now have a big burden of disease from obesity. They need and want medical care for it. And thankfully, scientific research is yielding amazing progress.
Abstracts for all presentations: https://link.springer.com/article/10.1007/s00125-023-05969-6
One, Two, Three: Multi-Agonists for Obesity at EASD 2023 - ConscienHealth
Today, EASD starts with a bang. Successive presentations on multi-agonists for obesity are scheduled for the next three days.
conscienhealth.org
Beyond CT-388, today’s session will offer data on retatrutide, cotadutide, survodutide, and pemvidutide. Then later we get data on tirzepatide – which is in line for FDA approval to treat obesity – from the SURMOUNT-4 study of weight maintenance out to 88 weeks of therapy. Yet another EASD session explores the mechanisms by which these multi-agonists may be acting in obesity and diabetes. In this session, we will get a glimpse of yet another GLP-1/GIP drug – CT-868.
.
.
.
This is a lot for all of us. Lifestyle medicine evangelists look at the world changing around them and they hardly know what to think. Some of them know that they hate it. They have a lifestyle program to sell and they seem to think that treating the physiologic problem of obesity is a threat to their business model. “Don’t make it complex when the metabolic impacts are obvious,” says one. “Ultraprocessed food consumption is designed to addict and adverse metabolic effects are imposed.”
We get it. If your whole world is built around coaching people with a minimal disease burden to prevent diabetes and obesity, then therapy for people with a bigger burden of disease is hard to comprehend.
But the fact is that many people now have a big burden of disease from obesity. They need and want medical care for it. And thankfully, scientific research is yielding amazing progress.